
Immatics biotechnologies
Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
Enterprise value
$105m
Share price
$5.28 IMTX
Company register number
HRB 382151 (Stuttgart)
Recent deals
Authorizing premium user...